AstraZeneca has launched the Cancer Care Africa programme in Kenya, a first-of-its-kind collaboration with the Ministry of Health, The Kenya Society of Haematology and Oncology (KESHO), Axios, the National Cancer Institute of Kenya (NCI), and other partners to improve cancer care in Kenya by equitably improving access and outcomes across the patient care pathway, from diagnosis through to treatment and beyond. Ahead of the launch, Cancer Care Africa has already donated ultrasound biopsy machines to seven hospitals across Kenya to enhance early prostate cancer diagnosis, as well as donating the country’s first biomarker testing machine for epidermal growth factor receptor (EGFR) mutations to Aga Khan University Hospital. Speaking during the event held at Serena Hotel in Nairobi Tuesday evening, Health Cabinet Secretary Nakhumicha S. Wafula described the launch as a significant step towards optimizing cancer care. “This collaborative initiative has the potential to significantly improve access to diagnosis, treatment, and care, ultimately saving lives and improving the well-being of Kenyans impacted by this disease, as well as their families and communities,” she said.